9CCJ

Dissecting human monoclonal antibody responses from mRNA and protein-based booster vaccinations against XBB1.5 SARS-CoV-2

Summary for 9CCJ

• Entry DOI: 10.2210/pdb9ccj/pdb
• EMDB information: 45444
• Descriptor: M2 Fab Heavy Chain, M2 Fab Light Chain, Spike glycoprotein, ... (6 entities in total)
• Functional Keywords: sars-cov-2, antibody, ntd, immune system, virus like particle, viral protein-immune system complex, viral protein/immune system
• Biological source: Homo sapiens; More
• Total number of polymer chains: 3
• Total formula weight: 184362.38

Authors

Bajic, G.,Civljak, A. (deposition date: 2024-06-21, release date: 2025-03-12, Last modification date: 2025-08-20)

Primary citation

Fantin, R.F.,Clark, J.J.,Cohn, H.,Jaiswal, D.,Bozarth, B.,Rao, V.,Civljak, A.,Lobo, I.,Nardulli, J.R.,Srivastava, K.,Yong, J.S.,Andreata-Santos, R.,Bushfield, K.,Lee, E.S.,Singh, G.,Kleinstein, S.H.,Krammer, F.,Simon, V.,Bajic, G.,Coelho, C.H.
Mapping of human monoclonal antibody responses to XBB.1.5 COVID-19 monovalent vaccines: a B cell analysis.
Lancet Microbe, 6:101103-101103, 2025

PubMed Abstract: The rapid emergence of highly transmissible and immune-evasive SARS-CoV-2 variants has required the reformulation of COVID-19 vaccines to target these evolving threats. Although previous infections and booster vaccinations can boost variant neutralisation, it remains uncertain whether monovalent vaccines-delivered via mRNA or protein-based platforms-can trigger novel B-cell responses specific to omicron XBB.1.5 variants. We sought to address this uncertainty by characterising the antibody repertoire of individuals receiving a monovalent booster vaccine.

PubMed: 40456237
DOI: 10.1016/j.lanmic.2025.101103

Experimental method

ELECTRON MICROSCOPY (2.37 Å)